Permite estimar en pacientes con fibrilación auricular: tanto el riesgo de infarto cerebral como el riesgo-beneficio de iniciar un tratamiento antitrombótico.I’ve just updated my SPARC tool for calculating your patients’ risk of stroke/thromboembolism and now major bleeding.
I’ve incorporated the now-published results from the ROCKET-AF trial (rivaroxaban) and theARISTOTLE trial (apixaban). I’ve corrected a few typos and calculation issues. I’ve added updated references for the above trials, plus a reference to a paper we’ve published recently casting doubt on the utility of the HAS-BLED scoring system.
